CTOs on the Move


 
Aso Corporation is dedicated to each and every customer it serves. In doing so, the company has developed business partnerships with their customers. It is for that reason that the company is structured whereby Account Managers work on a daily basis to
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.asocorp.com
  • 300 Sarasota Center Blvd
    Sarasota, FL USA 34240
  • Phone: 941.379.0300

Executives

Name Title Contact Details

Similar Companies

Rejuve

Rejuve is a Saratoga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RSB Spine

RSB Spine is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surgimedics

Surgimedics is a Lake City, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MIGUN USA CORPORATION

MIGUN USA CORPORATION is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.